Abstract
We present a queue model to inform ventilator capacity management under different COVID-19 pandemic scenarios. Our model was used to support ventilator capacity planning during the first wave of the COVID-19 epidemic in British Columbia (BC), Canada. The core of our framework is an extended Erlang loss model, which incorporates COVID-19 case projections, along with the proportion of cases requiring a ventilator, the delay from symptom onset to ventilation, non-COVID-19 ventilator demand, and ventilation time. We implemented our model using discrete event simulation to forecast ventilator utilization. The results predict when capacity would be reached and the rate at which patients would be unable to access a ventilator. We further determined the number of ventilators required to meet a performance indicator target for ventilator access. We applied our model to BC by calibrating to the BC Intensive Care Unit Database and by using local epidemic projections. Epidemic scenarios with and without reduced transmission, due to social distancing and other behavioral changes, were used to link public health interventions to operational impacts on ventilator utilization. The results predict that reduced transmission could potentially avert up to 50 deaths per day by ensuring that ventilator capacity would likely not be reached. Without reduced transmission, an additional 181 ventilators would be required to meet our performance indicator target that 95% of patients can access a ventilator immediately. Our model provides a tool for policy makers to quantify the interplay between public health interventions, necessary critical care resources, and performance indicators for patient access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a Partnership & Innovation Grant from the British Columbia Ministry of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Office of Research Ethics, Simon Fraser University, approved this study on the grounds that it is Quality Improvement / Quality Assurance.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
A github reference is given in the manuscript for BC Centre for Disease Control case projections used in the model.
